Koss Olinger Consulting LLC Makes New $94,000 Investment in Intellia Therapeutics, Inc. $NTLA

Koss Olinger Consulting LLC acquired a new position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 10,000 shares of the company’s stock, valued at approximately $94,000.

Other institutional investors have also added to or reduced their stakes in the company. Whipplewood Advisors LLC raised its holdings in Intellia Therapeutics by 114,900.0% in the second quarter. Whipplewood Advisors LLC now owns 3,450 shares of the company’s stock worth $32,000 after purchasing an additional 3,447 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Intellia Therapeutics by 56.4% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 4,590 shares of the company’s stock valued at $33,000 after acquiring an additional 1,655 shares in the last quarter. Harbour Investments Inc. increased its holdings in shares of Intellia Therapeutics by 76.7% during the first quarter. Harbour Investments Inc. now owns 5,214 shares of the company’s stock valued at $37,000 after acquiring an additional 2,264 shares in the last quarter. Quantbot Technologies LP increased its holdings in shares of Intellia Therapeutics by 846.4% during the first quarter. Quantbot Technologies LP now owns 6,663 shares of the company’s stock valued at $47,000 after acquiring an additional 5,959 shares in the last quarter. Finally, 49 Wealth Management LLC bought a new position in shares of Intellia Therapeutics during the first quarter valued at $74,000. Institutional investors own 88.77% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. William Blair downgraded Intellia Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday. Chardan Capital reduced their price target on Intellia Therapeutics from $60.00 to $48.00 and set a “buy” rating for the company in a report on Monday. Guggenheim downgraded Intellia Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday. Wells Fargo & Company restated an “overweight” rating and set a $45.00 price target (down from $50.00) on shares of Intellia Therapeutics in a report on Friday, August 8th. Finally, JMP Securities upgraded Intellia Therapeutics from a “market perform” rating to a “market outperform” rating and set a $33.00 price target for the company in a report on Monday, October 6th. Thirteen investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $28.05.

Intellia Therapeutics Stock Performance

NASDAQ NTLA opened at $14.79 on Tuesday. Intellia Therapeutics, Inc. has a one year low of $5.90 and a one year high of $28.25. The stock has a 50-day moving average of $16.90 and a 200 day moving average of $12.18. The company has a market capitalization of $1.59 billion, a price-to-earnings ratio of -3.15 and a beta of 2.37.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.99) EPS for the quarter, topping the consensus estimate of ($1.03) by $0.04. The company had revenue of $14.25 million during the quarter, compared to the consensus estimate of $12.26 million. Intellia Therapeutics had a negative return on equity of 57.48% and a negative net margin of 908.48%.Intellia Therapeutics’s revenue for the quarter was up 104.3% on a year-over-year basis. During the same period last year, the company earned ($1.52) EPS. On average, equities analysts predict that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current fiscal year.

Insider Activity

In other Intellia Therapeutics news, CAO Michael P. Dube sold 1,871 shares of the firm’s stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $17.38, for a total value of $32,517.98. Following the transaction, the chief accounting officer directly owned 55,266 shares of the company’s stock, valued at approximately $960,523.08. This trade represents a 3.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director William J. Chase bought 100,000 shares of the company’s stock in a transaction on Wednesday, August 20th. The stock was purchased at an average cost of $10.03 per share, for a total transaction of $1,003,000.00. Following the completion of the transaction, the director directly owned 134,693 shares of the company’s stock, valued at approximately $1,350,970.79. The trade was a 288.24% increase in their position. The disclosure for this purchase can be found here. Company insiders own 3.10% of the company’s stock.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.